Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...
One of the world’s largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...
Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI Conditional Labeling The rechargeable ...
The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that ...
InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...
DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results